Biosimilar Antibody-Drug Conjugates? Pfizer Isn’t Banking On It
‘The Regulatory Path Has To Be Determined. It Doesn’t Exist Today’
Pfizer’s $43bn agreement to acquire Seagen would layer its portfolio and pipeline with vastly complex antibody-drug conjugates – a class of drug that both parties feel might be almost immune to biosimilar competition.
